Gastrointestinal Cancer
From the Journals
Early-life antibiotic use may raise risk of early-onset CRC
"Individuals with genetic risk factors (i.e., family history of CRC) who have experienced early-life antibiotics use on a long-term basis are...
From the Journals
Cancer diagnoses, care access rise after Medicaid expansion
In Ohio, researchers found a substantial increase in diagnoses for all three cancers among Medicaid patients after expansion.
Latest News
ACP sticks with 50 as age to start CRC screening
The guidance notes that, although the rate of CRC has increased in younger adults, the incidence is 35.1 cases per 100,000 people, much lower than...
News from the FDA/CDC
FDA clears AI-assisted colonoscopy device
The device helps identify lesions in real time and is associated with a significant increase in the adenoma detection rate.
From the Journals
Short bursts of activity may cut cancer risk
Examples of such activity are vigorous housework, carrying heavy shopping bags around the grocery store, bursts of power walking, and playing high...
From the Journals
How staging laparoscopy informs pancreatic cancer care
“Staging laparoscopy should be considered in the majority of patients prior to resection and/or initiation of neoadjuvant therapy.”
From the Journals
Metachronous CRC risk after colonoscopy for positive FIT
“Results of this study could contribute to establish more restrictive polyp surveillance guidelines in a quality-assured setting.”
From the Journals
Does timing of surgery affect rectal cancer outcomes?
“Findings suggest that delaying surgery may improve tumor regression and decrease risk of distant metastasis but increase surgical complexity.”
Commentary
Brisk walking: No-cost option for patients to improve cancer outcomes
The bottom line is that physical activity is positive, is not expensive, and focuses on what the individual patient can do for themselves.
From the Journals
Lower-dose FOLFIRINOX effective, safer for pancreatic cancer
“The best dose modification protocol” remains to be determined and standardized for metastatic pancreatic cancer.
From the Journals
Was the fruquintinib trial for metastatic CRC a win?
“One could debate if 2.6 months of more time is worth the medication getting regulatory approval, or debate pricing when it’s approved, or delve...